首頁 > 市場調查報告書 > 醫療設備

整形外科美容整形

市場調查報告書

商品編碼

1930100

全球美容神經毒素市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的分析、未來預測（2026-2034）

Aesthetic Neurotoxin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034

出版日期: 2026年01月05日 | 出版商:

Fortune Business Insights Pvt. Ltd. | 英文 159 Pages | 商品交期: 請詢問到貨日

價格

簡介目錄圖表

美容神經毒素市場成長因素

由於對微創美容手術的需求不斷增長、人們對美容治療的認識不斷提高以及醫療旅遊業的蓬勃發展，全球美容神經毒素市場正經歷強勁增長。根據 Fortune Business Insights 的數據顯示，該市場在 2025 年的估值為 56 億美元，預計到 2026 年將達到 59.8 億美元。預計到 2034 年，該市場將進一步成長至 107 億美元，2026 年至 2034 年的複合年增長率 (CAGR) 為 7.54%。北美地區憑藉其完善的基礎設施、美容手術的高普及率和創新產品的推出，在 2025 年以 51.68% 的市場佔有率領先。

美容神經毒素（通常稱為肉毒桿菌）在醫學美容領域被廣泛應用，作為外科手術的替代方案。這些毒素有助於減少皺紋、細紋和其他老化跡象。國際美容旅遊（醫療美容旅遊）的增加進一步推動了市場成長。例如，韓國保健福祉部報告稱，到2023年，外國醫療遊客數量將增加144.2%，其中超過50%的治療項目為皮膚科和整形外科手術。

市場動態

市場驅動因素：

對微創手術需求的激增是主要的成長因素。非手術美容項目，尤其是肉毒桿菌注射療法，正日益受到歡迎。 2022年，美國共進行了8,877,991例肉毒桿菌注射，非手術美容計畫增加了23%。可支配收入的增加以及年輕一代對美容項目日益增長的接受度，進一步推動了市場的發展。

市場限制因素：

肉毒桿菌毒素的副作用（疼痛、腫脹、眼瞼下垂、流感樣症狀等）以及高昂的治療費用是其廣泛應用的障礙。在美國，肉毒桿菌注射的平均費用為每次450美元，部分療程甚至高達1,200美元，使得低收入者難以負擔。

市場機會：

持續的研發投入正為市場帶來顯著成長。各公司正在開發更安全、更有效的產品，以最大限度地減少副作用。例如，2023年10月，艾伯維公司公佈了其用於治療眉間紋的Trevibotulinumtoxin E III期臨床試驗的積極結果，凸顯了該市場的創新潛力。

市場挑戰：

假冒產品的氾濫對收入和病人安全都構成了重大風險。 2024年6月，美國疾病管制與預防中心（CDC）宣布，美國已通報17例因注射假冒神經毒素引起的不良反應病例，凸顯了監管和安全方面的挑戰。

市場趨勢：

技術進步：重組肉毒桿菌毒素正逐漸成為比傳統毒素更安全、免疫原性更低的替代品。 2024年9月，明麥生物技術有限公司的液體重組A型肉毒桿菌毒素製劑 "YY003" 獲得美國FDA批准，用於治療眉間紋。
醫療旅遊蓬勃發展：美容醫療旅遊的成長，尤其是在亞洲和中東地區，正在推動市場滲透。
策略聯盟：各大公司正致力於建立合作夥伴關係，以拓展分銷網絡，並更好地進入新興市場。

市場區隔分析

依應用領域劃分：

由於眉間紋在臨床上較為常見，且對美容矯正的需求較高，因此佔市場主導地位。 2025年1月公佈的IIIb期RELAX試驗的正面結果將進一步推動市場成長。
在Merz Aesthetics的XEOMIN於2023年7月獲得FDA批准用於治療臉部多處皺紋後，額紋細分市場的佔有率有所擴大。
由於人們對美觀的日益關注以及治療選擇的廣泛普及，魚尾紋細分市場也在成長。

依最終使用者劃分：

專科診所和皮膚科診所佔領先地位，受益於醫療旅遊和綜合美容服務。例如，2024年12月，美容診所吸引了15%的國際患者。
醫院和診所也因其嚴格遵守安全規程而繼續保持顯著的市場佔有率。 2023年，美國24.5%的美容手術是在醫院進行的。
其他細分市場包括研究機構和美容水療中心，它們透過研發活動提供穩定的成長機會。

區域展望

北美：預計2025年市場規模將達28.9億美元，2026年將達29.7億美元。這主要得益於美國較高的普及率和監管審批。艾伯維公司於2025年4月提交了用於治療眉間紋的肉毒桿菌毒素E的生物製品許可申請（BLA）。

歐洲：受人口老化和美容手術需求的推動。預計2026年，英國市場規模將達1.2億美元，德國市場規模將達2.4億美元。默茲美學公司於2023年7月擴大了Xeomin在歐洲的銷售。

亞太地區：預計成長將達到最高的複合年增長率。預計到2026年，日本市場規模將達到3.9億美元，中國市場將達到9.9億美元，印度市場將達到7,000萬美元。華東藥業與ATGC公司等策略合作夥伴關係將支持這一成長。

中東、非洲和拉丁美洲：由於可支配收入的增加和新產品的推出，預計將實現顯著增長。 2025年6月，大熊製藥在卡達推出了NABOTA，擴大了在海灣合作委員會地區的業務範圍。

市場分析、洞察與預測：依應用領域劃分
- 額紋
- 眉間紋
- 魚尾紋
- 其他
市場分析、洞察與預測：依最終用戶劃分
- 專科診所及皮膚科診所
- 醫院和醫療診所
- 其他
市場分析、洞察與預測：依地區劃分
- 北美
- 歐洲
- 亞太地區
- 拉丁美洲
- 中東和非洲

第六章北美美容神經毒素市場分析：洞察與預測（2021-2034）

依國家劃分
- 美國
- 加拿大

第七章歐洲美容神經毒素市場分析：洞察與預測（2021-2034）

依國家劃分
- 英國
- 德國
- 法國
- 西班牙
- 義大利
- 斯堪的納維亞
- 烏克蘭
- 歐洲其他地區

第八章亞太地區美容神經毒素市場分析：洞察與預測（2021-2034）

依國家劃分
- 日本
- 中國
- 印度
- 澳大利亞
- 韓國
- 泰國
- 台灣
- 亞太其他地區

第九章：拉丁美洲美容神經毒素市場分析：洞察與預測（2021-2034）

依國家劃分
- 巴西
- 墨西哥
- 智利
- 哥倫比亞
- 拉丁美洲其他地區

第十章：中東與非洲美容神經毒素市場分析：洞察與預測（2021-2034）

依國家劃分
- 埃及
- 伊朗
- 土耳其
- 黎巴嫩
- 阿拉伯聯合大公國
- 沙烏地阿拉伯
- 南非
- 中東和非洲其他地區

第11章競爭分析

全球市佔率分析（2025）
公司簡介
- AbbVie Inc.(Allergen Aesthetics)
- Ipsen Pharma
- Merz Pharma
- HUGEL, Inc.
- Evolus, Inc.
- GALDERMA
- REVANCE
- Supernus Pharmaceuticals, Inc.
- Medytox
- Shanghai Fosun Pharmaceutical(Group)Co., Ltd.
- DAEWOONG PHARMACEUTICAL CO., LTD

簡介目錄圖表

Product Code: FBI113750

Growth Factors of aesthetic neurotoxin Market

The global aesthetic neurotoxin market is witnessing robust growth due to the increasing demand for minimally invasive cosmetic procedures, rising awareness of aesthetic treatments, and expanding medical tourism. According to Fortune Business Insights, the market was valued at USD 5.6 billion in 2025, is projected to reach USD 5.98 billion in 2026, and is expected to expand to USD 10.7 billion by 2034, representing a CAGR of 7.54% during 2026-2034. North America dominated the market in 2025 with a 51.68% share, driven by strong infrastructure, high adoption of cosmetic procedures, and innovative product launches.

Aesthetic neurotoxins, commonly known as botulinum toxins, are widely used in aesthetic medicine as alternatives to surgical procedures. These toxins help in reducing wrinkles, fine lines, and other signs of aging. The market's growth is further supported by increasing cosmetic tourism. For example, in Korea, the Ministry of Health and Welfare reported a 144.2% increase in foreign medical visitors, with dermatology and plastic surgery procedures accounting for over 50% of the treatments in 2023.

Market Dynamics

Market Drivers:

The surge in demand for minimally invasive procedures has been a key growth driver. Non-surgical procedures, particularly botulinum toxin treatments, gained popularity with 8,877,991 Botox procedures performed in 2022, reflecting a 23% increase in non-surgical aesthetic procedures. Rising disposable incomes and the normalization of cosmetic enhancements in younger populations further bolster the market.

Market Restraints:

The adverse effects of botulinum toxins, such as pain, swelling, droopy eyelids, and flu-like symptoms, and the high cost of procedures limit adoption. In the U.S., Botox treatment costs average USD 450 per session, with some treatments reaching USD 1,200, restricting access for lower-income populations.

Market Opportunities:

Ongoing research and development offers significant growth avenues. Companies are developing safer and more effective products to minimize adverse effects. For instance, in October 2023, AbbVie reported positive Phase 3 trial results for trenibotulinumtoxinE for glabellar lines, highlighting innovation potential in the market.

Market Challenges:

The prevalence of counterfeit products poses a significant risk, both to revenue and patient safety. The CDC reported 17 cases of adverse reactions in the U.S. in June 2024 due to counterfeit neurotoxin injections, highlighting regulatory and safety challenges.

Market Trends

Technological Advancements: Recombinant botulinum toxins are emerging as safer, less immunogenic alternatives to traditional toxins. MingMed Biotechnology received US FDA approval for YY003 in September 2024, a liquid recombinant BoNT/A for glabellar lines.
Medical Tourism Expansion: Growth in aesthetic tourism, particularly in Asia and the Middle East, is increasing market adoption.
Strategic Collaborations: Key players focus on partnerships to expand distribution networks and access emerging markets.

Segmentation Analysis

By Application:

Glabellar lines dominate the market due to clinical prevalence and high demand for cosmetic correction. Positive Phase IIIb RELAX trial results in January 2025 further support growth.
Forehead wrinkles segment is gaining share after Merz Aesthetics' FDA approval of XEOMIN in July 2023 for treating multiple upper facial lines.
Crow's feet are also growing due to rising cosmetic concerns and treatment adoption.

By End-User:

Specialty & dermatology clinics lead, benefiting from medical tourism and comprehensive cosmetic services. For example, in December 2024, The Esthetic Clinics attracted 15% international patients.
Hospitals & clinics also maintain significant market share due to adherence to strict safety protocols. In 2023, 24.5% of U.S. cosmetic procedures were conducted in hospitals.
Others include research institutes and aesthetic spas, offering stable growth opportunities through R&D activities.

Regional Outlook

North America: Market value USD 2.89 billion in 2025, projected to reach USD 2.97 billion by 2026, led by U.S. high adoption rates and regulatory approvals. AbbVie submitted a BLA for trenibotulinumtoxinE in April 2025 for glabellar lines.

Europe: Driven by the elderly population and cosmetic procedures demand. U.K. market USD 0.12 billion by 2026, Germany USD 0.24 billion by 2026. Merz Aesthetics expanded XEOMIN across Europe in July 2023.

Asia Pacific: Projected to grow at the highest CAGR. Japan market USD 0.39 billion by 2026, China USD 0.99 billion, India USD 0.07 billion, supported by strategic collaborations like Huadong Medicine and ATGC Co., Ltd.

Latin America & Middle East & Africa: Substantial growth due to rising disposable incomes and new product launches. In June 2025, Daewoong Pharmaceutical launched NABOTA in Qatar, expanding GCC availability.

Competitive Landscape

Key players include AbbVie Inc., Ipsen Pharma, Merz Pharma, Hugel Inc., Evolus, GALDERMA, REVANCE, and Supernus Pharmaceuticals. The market is consolidated, driven by product innovation, strategic collaborations, and regulatory approvals. Notable developments include Allergan Aesthetics launching BOTOX Cosmetic for masseter muscle prominence in China in September 2024.

Conclusion

The aesthetic neurotoxin market is expected to grow from USD 5.6 billion in 2025 to USD 10.7 billion by 2034, driven by minimally invasive procedure demand, increasing cosmetic tourism, technological advancements, and strategic partnerships. North America leads globally, followed by Europe and Asia Pacific, while innovations in recombinant toxins and medical tourism adoption are key to future growth.

Segmentation By Application

Forehead Wrinkles
Glabellar Lines
Crow's Feet
Others

By End-User

Specialty & Dermatology Clinics
Hospitals & Clinics
Others

By Region

North America (By Application, End-User, and Country)
- U.S. (By Application)
- Canada (By Application)
Europe (By Application, End-User, and Country)
- Germany (By Application)
- U.K. (By Application)
- France (By Application)
- Italy (By Application)
- Spain (By Application)
- Scandinavia (By Application)
- Ukraine (By Application)
- Rest of Europe (By Application)
Asia Pacific (By Application, End-User, and Country /sub-region)
- China (By Application)
- India (By Application)
- Japan (By Application)
- Australia (By Application)
- South Korea (By Application)
- Thailand (By Application)
- Taiwan (By Application)
- Rest of the Asia Pacific (By Application)
Latin America (By Application, End-User, and Country /sub-region)
- Brazil (By Application)
- Mexico (By Application)
- Colombia (By Application)
- Argentina (By Application)
- Venezuela (By Application)
- Chile (By Application)
- Rest of Latin America (By Application)
Middle East & Africa (By Application, End-User, and Country /sub-region)
- UAE (By Application)
- Saudi Arabia (By Application)
- Rest of GCC (By Application)
- South Africa (By Application)
- Turkey (By Application)
- Egypt (By Application)
- Lebanon (By Application)
- Iran (By Application)
- Rest of the Middle East & Africa (By Application)

Table of Content

1. Introduction

1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends

4. Key Insights

4.1. Overview of the Number of Aesthetic Procedures, By Key Countries
4.2. Overview of Price Analysis of Types of Aesthetic Procedures
4.3. Overview of Regulatory Scenario, By Key Countries
4.4. Overview of Reimbursement Scenario, By Key Countries
4.5. New Product Launches, By Key Players
4.6. Pipeline Analysis, By Key Players
4.7. Imports/Sales Overview of Key Aesthetic Neurotoxin Products Approved by MHLW (Japan)

5. Global Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2021-2034

5.1. Market Analysis, Insights and Forecast - By Application
- 5.1.1. Forehead Wrinkles
- 5.1.2. Glabellar Lines
- 5.1.3. Crow's Feet
- 5.1.4. Others
5.2. Market Analysis, Insights and Forecast - By End-User
- 5.2.1. Specialty & Dermatology Clinics
- 5.2.2. Hospitals & Clinics
- 5.2.3. Others
5.3. Market Analysis, Insights and Forecast - Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Latin America
- 5.3.5. Middle East & Africa

6. North America Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2021-2034

6.1. Market Analysis, Insights and Forecast - By Application
- 6.1.1. Forehead Wrinkles
- 6.1.2. Glabellar Lines
- 6.1.3. Crow's Feet
- 6.1.4. Others
6.2. Market Analysis, Insights and Forecast - By End-User
- 6.2.1. Specialty & Dermatology Clinics
- 6.2.2. Hospitals & Clinics
- 6.2.3. Others
6.3. Market Analysis, Insights and Forecast - By Country
- 6.3.1. U.S.
- 6.3.2. Canada

7. Europe Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2021-2034

7.1. Market Analysis, Insights and Forecast - By Application
- 7.1.1. Forehead Wrinkles
- 7.1.2. Glabellar Lines
- 7.1.3. Crow's Feet
- 7.1.4. Others
7.2. Market Analysis, Insights and Forecast - By End-User
- 7.2.1. Specialty & Dermatology Clinics
- 7.2.2. Hospitals & Clinics
- 7.2.3. Others
7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.3.1. U.K.
- 7.3.2. Germany
- 7.3.3. France
- 7.3.4. Spain
- 7.3.5. Italy
- 7.3.6. Scandinavia
- 7.3.7. Ukraine
- 7.3.8. Rest of Europe

8. Asia Pacific Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2021-2034

8.1. Market Analysis, Insights and Forecast - By Application
- 8.1.1. Forehead Wrinkles
- 8.1.2. Glabellar Lines
- 8.1.3. Crow's Feet
- 8.1.4. Others
8.2. Market Analysis, Insights and Forecast - By End-User
- 8.2.1. Specialty & Dermatology Clinics
- 8.2.2. Hospitals & Clinics
- 8.2.3. Others
8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.3.1. Japan
- 8.3.2. China
- 8.3.3. India
- 8.3.4. Australia
- 8.3.5. South Korea
- 8.3.6. Thailand
- 8.3.7. Taiwan
- 8.3.8. Rest of Asia Pacific

9. Latin America Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2021-2034

9.1. Market Analysis, Insights and Forecast - By Application
- 9.1.1. Forehead Wrinkles
- 9.1.2. Glabellar Lines
- 9.1.3. Crow's Feet
- 9.1.4. Others
9.2. Market Analysis, Insights and Forecast - By End-User
- 9.2.1. Specialty & Dermatology Clinics
- 9.2.2. Hospitals & Clinics
- 9.2.3. Others
9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.3.1. Brazil
- 9.3.2. Mexico
- 9.3.3. Chile
- 9.3.4. Colombia
- 9.3.5. Rest of Latin America

10. Middle East & Africa Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2021-2034

10.1. Market Analysis, Insights and Forecast - By Application
- 10.1.1. Forehead Wrinkles
- 10.1.2. Glabellar Lines
- 10.1.3. Crow's Feet
- 10.1.4. Others
10.2. Market Analysis, Insights and Forecast - By End-User
- 10.2.1. Specialty & Dermatology Clinics
- 10.2.2. Hospitals & Clinics
- 10.2.3. Others
10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.3.1. Egypt
- 10.3.2. Iran
- 10.3.3. Turkey
- 10.3.4. Lebanon
- 10.3.5. UAE
- 10.3.6. Saudi Arabia
- 10.3.7. South Africa
- 10.3.8. Rest of Middle East and Africa

11. Competitive Analysis

11.1. Global Market Share Analysis (2025)
11.2. Company Profiles
- 11.2.1. AbbVie Inc. (Allergen Aesthetics)
  - 11.2.1.1. Overview
  - 11.2.1.2. Products
  - 11.2.1.3. SWOT Analysis
  - 11.2.1.4. Recent Developments
  - 11.2.1.5. Strategies
  - 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Ipsen Pharma
  - 11.2.2.1. Overview
  - 11.2.2.2. Products
  - 11.2.2.3. SWOT Analysis
  - 11.2.2.4. Recent Developments
  - 11.2.2.5. Strategies
  - 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Merz Pharma
  - 11.2.3.1. Overview
  - 11.2.3.2. Products
  - 11.2.3.3. SWOT Analysis
  - 11.2.3.4. Recent Developments
  - 11.2.3.5. Strategies
  - 11.2.3.6. Financials (Based on Availability)
- 11.2.4. HUGEL, Inc.
  - 11.2.4.1. Overview
  - 11.2.4.2. Products
  - 11.2.4.3. SWOT Analysis
  - 11.2.4.4. Recent Developments
  - 11.2.4.5. Strategies
  - 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Evolus, Inc.
  - 11.2.5.1. Overview
  - 11.2.5.2. Products
  - 11.2.5.3. SWOT Analysis
  - 11.2.5.4. Recent Developments
  - 11.2.5.5. Strategies
  - 11.2.5.6. Financials (Based on Availability)
- 11.2.6. GALDERMA
  - 11.2.6.1. Overview
  - 11.2.6.2. Products
  - 11.2.6.3. SWOT Analysis
  - 11.2.6.4. Recent Developments
  - 11.2.6.5. Strategies
  - 11.2.6.6. Financials (Based on Availability)
- 11.2.7. REVANCE
  - 11.2.7.1. Overview
  - 11.2.7.2. Products
  - 11.2.7.3. SWOT Analysis
  - 11.2.7.4. Recent Developments
  - 11.2.7.5. Strategies
  - 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Supernus Pharmaceuticals, Inc.
  - 11.2.8.1. Overview
  - 11.2.8.2. Products
  - 11.2.8.3. SWOT Analysis
  - 11.2.8.4. Recent Developments
  - 11.2.8.5. Strategies
  - 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Medytox
  - 11.2.9.1. Overview
  - 11.2.9.2. Products
  - 11.2.9.3. SWOT Analysis
  - 11.2.9.4. Recent Developments
  - 11.2.9.5. Strategies
  - 11.2.9.6. Financials (Based on Availability)
- 11.2.10. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  - 11.2.10.1. Overview
  - 11.2.10.2. Products
  - 11.2.10.3. SWOT Analysis
  - 11.2.10.4. Recent Developments
  - 11.2.10.5. Strategies
  - 11.2.10.6. Financials (Based on Availability)
- 11.2.11. DAEWOONG PHARMACEUTICAL CO., LTD
  - 11.2.11.1. Overview
  - 11.2.11.2. Products
  - 11.2.11.3. SWOT Analysis
  - 11.2.11.4. Recent Developments
  - 11.2.11.5. Strategies
  - 11.2.11.6. Financials (Based on Availability)

簡介目錄圖表

List of Tables

Table 1: Global Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2021-2034
Table 2: Global Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
Table 3: Global Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Region, 2021-2034
Table 4: North America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2021-2034
Table 5: North America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
Table 6: North America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country, 2021-2034
Table 7: Europe Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2021-2034
Table 8: Europe Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
Table 9: Europe Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
Table 10: Asia Pacific Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2021-2034
Table 11: Asia Pacific Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
Table 12: Asia Pacific Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
Table 13: Latin America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2021-2034
Table 14: Latin America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
Table 15: Latin America Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
Table 16: Middle East & Africa Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Application, 2021-2034
Table 17: Middle East & Africa Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
Table 18: Middle East & Africa Aesthetic Neurotoxin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

Figure 1: Global Aesthetic Neurotoxin Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
Figure 2: Global Aesthetic Neurotoxin Market Value Share (%), by Application, 2025 & 2034
Figure 3: Global Aesthetic Neurotoxin Market Value Share (%), by End-User, 2025 & 2034
Figure 4: Global Aesthetic Neurotoxin Market Value Share (%), by Region, 2025 & 2034
Figure 5: North America Aesthetic Neurotoxin Market Value (USD billion), by Application, 2025 & 2034
Figure 6: North America Aesthetic Neurotoxin Market Value Share (%), by Application, 2025
Figure 7: North America Aesthetic Neurotoxin Market Value (USD billion), by End-User, 2025 & 2034
Figure 8: North America Aesthetic Neurotoxin Market Value Share (%), by End-User, 2025
Figure 9: North America Aesthetic Neurotoxin Market Value (USD billion), by Country, 2025 & 2034
Figure 10: North America Aesthetic Neurotoxin Market Value Share (%), by Country, 2025
Figure 11: Europe Aesthetic Neurotoxin Market Value (USD billion), by Application, 2025 & 2034
Figure 12: Europe Aesthetic Neurotoxin Market Value Share (%), by Application, 2025
Figure 13: Europe Aesthetic Neurotoxin Market Value (USD billion), by End-User, 2025 & 2034
Figure 14: Europe Aesthetic Neurotoxin Market Value Share (%), by End-User, 2025
Figure 15: Europe Aesthetic Neurotoxin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
Figure 16: Europe Aesthetic Neurotoxin Market Value Share (%), by Country/ Sub-region, 2025
Figure 17: Asia Pacific Aesthetic Neurotoxin Market Value (USD billion), by Application, 2025 & 2034
Figure 18: Asia Pacific Aesthetic Neurotoxin Market Value Share (%), by Application, 2025
Figure 19: Asia Pacific Aesthetic Neurotoxin Market Value (USD billion), by End-User, 2025 & 2034
Figure 20: Asia Pacific Aesthetic Neurotoxin Market Value Share (%), by End-User, 2025
Figure 21: Asia Pacific Aesthetic Neurotoxin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
Figure 22: Asia Pacific Aesthetic Neurotoxin Market Value Share (%), by Country/ Sub-region, 2025
Figure 23: Latin America Aesthetic Neurotoxin Market Value (USD billion), by Application, 2025 & 2034
Figure 24: Latin America Aesthetic Neurotoxin Market Value Share (%), by Application, 2025
Figure 25: Latin America Aesthetic Neurotoxin Market Value (USD billion), by End-User, 2025 & 2034
Figure 26: Latin America Aesthetic Neurotoxin Market Value Share (%), by End-User, 2025
Figure 27: Latin America Aesthetic Neurotoxin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
Figure 28: Latin America Aesthetic Neurotoxin Market Value Share (%), by Country/ Sub-region, 2025
Figure 29: Middle East & Africa Aesthetic Neurotoxin Market Value (USD billion), by Application, 2025 & 2034
Figure 30: Middle East & Africa Aesthetic Neurotoxin Market Value Share (%), by Application, 2025
Figure 31: Middle East & Africa Aesthetic Neurotoxin Market Value (USD billion), by End-User, 2025 & 2034
Figure 32: Middle East & Africa Aesthetic Neurotoxin Market Value Share (%), by End-User, 2025
Figure 33: Middle East & Africa Aesthetic Neurotoxin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
Figure 34: Middle East & Africa Aesthetic Neurotoxin Market Value Share (%), by Country/ Sub-region, 2025
Figure 35: Global Aesthetic Neurotoxin Market Share (%), by Company, 2025